Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hayet Frayssinet"'
Autor:
Hayet Frayssinet, Thomas J. Schnitzer, Michael A. Weber, William B. White, Brigitte Duquesroix, George L. Bakris
Publikováno v:
The American Journal of Cardiology. 107:1338-1345
Nonsteroidal anti-inflammatory drugs are associated with increases in blood pressure (BP), particularly in patients treated with antihypertensive therapy. Naproxcinod is a nitric oxide-donating cyclooxygenase inhibitor in development for osteoarthrit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cac2ca2b6899d277b1c93fc702e1ec0
https://doi.org/10.1016/j.amjcard.2010.12.046
https://doi.org/10.1016/j.amjcard.2010.12.046
Autor:
Hayet Frayssinet, Thomas J. Schnitzer, Brigitte Duquesroix, Maarten Beekman, Marc C. Hochberg, Christopher E. Marrero
Publikováno v:
Seminars in Arthritis and Rheumatism. 40:285-297
Comparison of naproxcinod (375 and 750 mg), placebo (up to 13 weeks), and naproxen 500 mg (all bid) for treatment of osteoarthritis (OA) signs and symptoms.A 53-week, randomized, double-blind, parallel-group study. One thousand twenty patients with p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed7182b67072ad892a20d8e8b336b520
https://doi.org/10.1016/j.semarthrit.2010.06.002
https://doi.org/10.1016/j.semarthrit.2010.06.002
Autor:
Paolo Verdecchia, Thierry Ferreira, Christoph Baerwald, Hayet Frayssinet, Brigitte Duquesroix
Publikováno v:
Arthritis & Rheumatism. 62:3635-3644
Objective To test the superiority of naproxcinod compared with placebo in relieving the signs and symptoms of hip osteoarthritis and to assess the safety of naproxcinod and its effects on blood pressure. Methods In a 13-week, randomized, double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88088fc529cbd90a169ca6350af7fd0f
https://doi.org/10.1002/art.27694
https://doi.org/10.1002/art.27694
Autor:
Raymond Townsend, Neville Bittar, Jeffrey Rosen, William Smith, Andrea Ramsay, Steven Chrysant, Robert Weiss, Hayet Frayssinet, Brigitte Duquesroix
Publikováno v:
Circulation. 116
Background : Naproxcinod is a first-in-class Cyclooxygenase Inhibiting Nitric Oxide Donator (CINOD) with anti-inflammatory and analgesic properties. Naproxcinod inhibits both COX-1 and COX-2 enzymes. It is well recognized that NSAIDs and coxibs may e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3eece3bfe8269231a2fbb6e56c98e086
https://doi.org/10.1161/circ.116.suppl_16.ii_609
https://doi.org/10.1161/circ.116.suppl_16.ii_609